Home › Companies › ENTA

Enanta Pharmaceuticals

ENTA Lead: Phase 3 ★ Read the deep dive → 6 Biotech Distilled articles ↓

Dermatology Immunology Infectious Disease Small Molecule

Most recent annual filing: 2025-11-15

Pipeline (6 active programs)

zelicapavir

EDP-938

Small Molecule Target: RSV N-protein, N-protein

Respiratory Syncytial Virus Phase 3 oral

EDP-323

Small Molecule Target: RSV L-protein

Respiratory Syncytial Virus Phase 2 oral

EDP-235

Small Molecule Target: 3CL protease

COVID-19 Phase 2 oral

EDP-514

Small Molecule Target: HBV core protein

Chronic Hepatitis B Phase 1

EDP-978

Small Molecule Target: KIT

Chronic Spontaneous Urticaria Phase 1 oral

EPS-3903

Small Molecule Target: STAT6

Atopic Dermatitis Preclinical oral

Biotech Distilled coverage (6)

2026-07-02 UPDATE: Enanta (ENTA) - The Shelf Wasn’t Just Housekeeping
2026-06-23 UPDATE: Enanta (ENTA) - The Federal Circuit Tore Up One of the Lottery Tickets
2026-06-18 UPDATE: Enanta (ENTA) - The FDA Said Yes. The Market Said No.
2026-05-12 UPDATE: Enanta (ENTA) - Q2 FY26 Sets the Clock on Zelicapavir 🔒 Paid
2026-02-14 UPDATE: Enanta (ENTA) - Q1 2026 Financial Update 🔒 Paid
2026-02-10 Enanta Pharmaceuticals (ENTA): Scientific Deep Dive for Lead and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.